tils prolong pfs compared with pembrolizumab in advanced melanoma
Published 2 years ago • 71 plays • Length 0:37Download video MP4
Download video MP3
Similar videos
-
1:04
optimizing tils as a novel immunotherapy strategy in metastatic melanoma
-
0:51
what role will tils play in treating patients with melanoma?
-
1:44
intratumoral immunotherapy with bo-112 pembrolizumab in patients with anti-pd1 refractory melanoma
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
0:56
treating patients with melanoma who progressed on anti-pd-l1 with lenvatinib and pembrolizumab
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
3:37
exploring the role of lifileucel in the treatment of melanoma brain metastases
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
2:34
keynote-029: pembrolizumab with ipilimumab for melanoma
-
9:40
reducing recurrence of advanced melanoma with pembrolizumab
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
4:27
key updates in immunotherapies for melanoma
-
2:05
long-term efficacy of pembrolizumab in advanced melanoma
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial